form8-kdtd092514.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

___________________

FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report: September 25, 2014
(Date of earliest event reported)


BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada
000-54402
91-1835664
(State or Other Jurisdiction of Incorporation)
(Commission File No.)
(IRS Employer Identification Number)

555 Heritage Drive, Jupiter, Florida
    33458
(Address of Principal Executive Offices)
(Zip Code)


Registrant's telephone number, including area code: (561) 904-6070


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


____
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
____
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
____
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
____
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

 

 
Item 3.02.
Unregistered Sales of Equity Securities.

Between September 16, 2014 and September 25, 2014, BioRestorative Therapies, Inc. (the “Company”) issued an aggregate of 1,559,999 shares of common stock of the Company for an aggregate purchase price of $465,000.  In connection with the share issuances, the Company issued to the subscribers warrants for the purchase of an aggregate of 374,999 shares of common stock at an exercise price of $.75 per share.  The warrants have a term of five years.

In addition, between September 11, 2014 and September 23, 2014, the Company issued an aggregate of 32,347 shares of common stock of the Company in consideration of services rendered valued at $7,515.

Further, between September 11, 2014 and September 16, 2014, the Company issued an aggregate of 279,027 shares of common stock of the Company in exchange for outstanding indebtedness in the aggregate amount of $60,228, inclusive of accrued and unpaid interest.

For each of the securities issuances, the Company relied upon Section 4(a)(2) of the Securities Act of 1933, as amended, as transactions by an issuer not involving any public offering. For each such transaction, the Company did not use general solicitation or advertising to market the securities, the securities were offered to a limited number of persons, the investors had access to information regarding the Company (including information contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, Quarterly Reports on Form 10-Q for the periods ended March 31, 2014 and June 30, 2014 and Current Reports on Form 8-K filed with the Securities and Exchange Commission and press releases made by the Company), and management of the Company was available to answer questions from prospective investors.  The Company reasonably believes that each of the investors is an accredited investor.



 
 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  BIORESTORATIVE THERAPIES, INC.  
       
Dated: September 29, 2014
By:
/s/ Mark Weinreb  
    Mark Weinreb   
    Chief Executive Officer